IMMUNOPRECISE ANTIBODIES LTD Sample Clauses

IMMUNOPRECISE ANTIBODIES LTD a company duly formed under the laws of the Province of British Columbia, with its principal office located at Xxxx 0000, 0000 Xxxxxxx Xxxxxx, Xxxxxxxx, XX X0X 0X0 (the “Purchaser”) U-PROTEIN EXPRESS B.V., a company duly formed under the laws of the Netherlands, with its principal office located at Life Sciences Incubator, Utrecht, Science Park, Yalelaan, 62, 3584 CM, Utrecht, The Netherlands, registered with the trade register of the Chamber of Commerce under number 30230407. (“U-Protein” or the “Company”) THE UNDERSIGNED SHAREHOLDERS OF U-PROTEIN EXPRESS B.V. (collectively referred to as the “U-Protein Shareholders” or “Sellers”)
AutoNDA by SimpleDocs
IMMUNOPRECISE ANTIBODIES LTD a company duly formed under the laws of the Province of British Columbia, with its principal office located at Xxxx 0000, 0000 Xxxxxxx Xxxxxx, Xxxxxxxx, XX X0X 0X0 (the Purchaser);
IMMUNOPRECISE ANTIBODIES LTD having its business address at U.Vic Vancouver Island Technology Park, #3204-4464 Xxxxxxx Xxxxxx, Xxxxxxxx, XX, Xxxxxx, X0X 0X0 AND: XXXXXX XXXXXX, having an address at Mr. Xxxxxxxxxxxxx 00, 0000 XX Xxxx, The Netherlands (Hereinafter collectively referred to as the “Parties”)
IMMUNOPRECISE ANTIBODIES LTD. TERMS AGREEMENT
IMMUNOPRECISE ANTIBODIES LTD a limited liability company, having its business address at U.Vic Vancouver Island Technology Park, #3204-4464 Xxxxxxx Xxxxxx, Xxxxxxxx, XX, Xxxxxx, X0X 0X0 (ImmunoPrecise Antibodies). ModiQuest Research, Immulease, ImmunoPrecise Netherlands and ImmunoPrecise Antibodies are hereinafter jointly also referred to as the IPA Group Companies and each also an IPA Group Company. The IPA Group Companies, Immusys and Raats are hereinafter jointly referred to as the Parties and each as a Party.

Related to IMMUNOPRECISE ANTIBODIES LTD

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Preceptor A per diem Registered Nurse 2 may serve as a preceptor after successfully completing a preceptor workshop or equivalent documented training and agreeing to and being appointed to be specifically responsible for planning, organizing, and evaluating the new skill development of one or more RNs as appropriate enrolled in a defined orientation program, the parameters of which have been set forth in writing by the Employer. This includes teaching, clinical supervision, role modeling, feedback, evaluation (verbal and written) and follow up of the new or transferring employee. The per diem RN 2 preceptor is eligible to receive preceptor premium pay when actually engaged in preceptor role responsibilities with/on behalf of the orienting RN. A per diem RN 2 substituting for the original preceptor during a period of absence and who has been designated to carry out the preceptor's complete responsibility (including following and/or adjusting the plan to meet learning needs and providing oral and written evaluation input) will receive preceptor pay. A preceptor may be assigned to a student when it is determined by the Employer that the employee has completed the required preceptor training or has agreed to and been appointed a preceptor. The employee is specifically responsible for planning, organizing, and evaluating the new skill development of the student as appropriately enrolled in a defined program, the parameters of which have been set forth in writing by the Employer. This includes teaching, clinical supervision, role modeling, feedback, evaluation (verbal and written) and follow up of the student.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!